Day: September 12, 2025

HONG KONG, Sept. 12, 2025 (GLOBE NEWSWIRE) — MoneyHero Limited (NASDAQ: MNY) (“MoneyHero” or the “Company”), a leading personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia, today announced that Credit Hero Club has launched its invite-only beta version to a selected group of MoneyHero users, following a successful alpha release to internal MoneyHero and TransUnion users at the end of Q2 2025. Beta testing is underway and will continue through a structured evaluation period of approximately three weeks, after which the Company will finalise product adjustments ahead of the public launch targeted for Q4 2025. Credit Hero Club, developed in partnership with TransUnion (NYSE:TRU), a global information and insights company, aims to provide users one-stop access to...

SCOTTSDALE, Ariz., Sept. 11, 2025 (GLOBE NEWSWIRE) — Black Rock Coffee Bar, Inc. (“Black Rock Coffee Bar”) today announced the pricing of the initial public offering of 14,705,882 shares of its Class A common stock at a price to the public of $20.00 per share. Black Rock Coffee Bar has granted the underwriters a 30-day option to purchase up to an additional 2,205,882 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions. Black Rock Coffee Bar shares are expected to begin trading on the Nasdaq Global Market on September 12, 2025 under the ticker symbol “BRCB.” The offering is expected to close on September 15, 2025, subject to customary closing conditions. J.P. Morgan, Jefferies, Morgan Stanley and Baird are acting as lead book-running managers for the offering. Stifel...

— HUTCHMED will host in-person presentation and online webinar on Friday, October 31 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a Research & Development update in Shanghai, China, and via webcast on Friday, October 31, 2025. During the event, Dr. Michael Shi, Executive Vice President, Head of R&D and Chief Medical Officer of HUTCHMED, will share insights into the Company’s R&D strategy and vision. This will include an overview of the Company’s Antibody Targeted Therapy Conjugates platform, featuring its lead candidate HMPL-A251, as well as updates on late-stage pipeline development. The in-person event will be held in Shanghai from 3:00 p.m. to 5:00 p.m. HKT and conducted in Chinese...